Drug costs in context: assessing drug costs in cost-of-illness analyses.
JournalDrugs in Context
PublisherBioexcel Publishing Ltd.
MetadataShow full item record
AbstractCost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates. The complexity of the pharmaceutical supply chain and contractual relationships between manufacturers, wholesalers, pharmacies and payers create challenges for researchers attempting to include drug costs in COI analyses. This article aims to provide contextual information for a general audience interested in conducting or evaluating COI studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.
Rights/TermsCopyright © 2022 Mattingly II TJ, Weathers S.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19574
- Suicidal Ideation
- Authors: Harmer B, Lee S, Duong TvH, Saadabadi A
- Issue date: 2022 Jan
- Cost-of-illness studies : a review of current methods.
- Authors: Akobundu E, Ju J, Blatt L, Mullins CD
- Issue date: 2006
- The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
- Authors: Seuring T, Archangelidi O, Suhrcke M
- Issue date: 2015 Aug
- Cost-of-illness studies. Useful for health policy?
- Authors: Koopmanschap MA
- Issue date: 1998 Aug
- Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients.
- Authors: Howell S, Yin PT, Robinson JC
- Issue date: 2021 Aug